ArticleJournal of vascular surgery cases and innovative techniques2026
Single-center experience using Endologix anatomically fixated endograft device for treatment of aortoiliac occlusive disease.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The covered endovascular reconstruction of the aortic bifurcation (CERAB) technique was developed in recent years as a novel surgical intervention for aortoiliac occlusive disease (AIOD). One tool frequently used in such procedures is the anatomically fixated endograft (AFX), manufactured by Endologix. The present study aimed to review the outcomes of patients with AIOD after CERAB procedure using the Endologix AFX device. Methods: This is an institutional review board-approved retrospective study investigating the experience of a single center in using Endologix's AFX device as CERAB for AIOD from September 2018 to June 2024. Data were obtained from the medical records of all patients who underwent the CERAB procedure with the Endologix device during the designated time frame. The primary outcomes included 30-day mortality and postoperative complications. Secondary outcomes included changes in ABI and need for reintervention. Results: We identified 24 patients as having undergone CERAB in the period September 2018 to June 2024. The average age of the patients was 71.29 ± 7.56 years. The average length of procedure was 3 hours 30 minutes ± 0.09 hours. The median estimated blood loss for CERAB was 127.5 mL (interquartile range, 50-300 mL). The median postoperative length of stay for CERAB was 2.5 days (range, 1-56 days). Ten patients experienced postoperative complications (41.67%) overall, which included respiratory failure (16.67%), acute renal insufficiency (8.33%), hematoma (8.33%), and infection (8.33%). Four cases required reintervention (16.7%), and mortality within 30 days of procedure was 4.17% (n = 1). Postoperatively, 83.33% of evaluated patients experienced improved ABIs. The average change in the ankle-brachial index was 0.20 ± 0.27 on the right and 0.16 ± 0.22on the left. Conclusions: Overall, the CERAB procedure using the AFX device from Endologix demonstrated a high technical success rate and low rate of postoperative complications and mortality. The short-term results suggest that the use of AFX in CERAB is an effective and relatively safe treatment option for patients with AIOD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.